OBJECTIVES: F-HX4 is a novel positron emission tomography (PET) tracer for imaging hypoxia. The purpose of this study was to determine the biodistribution and estimate the radiation dose of F-HX4 using whole-body PET/computed tomography (CT) scans in monkeys and humans. METHODS: Successive whole-body PET/CT scans were done after the injection of F-HX4 in four healthy humans (422±142 MBq) and in three rhesus monkeys (189±3 MBq). Biodistribution was determined from PET images and organ doses were estimated using OLINDA/EXM software. RESULTS: The bladder, liver, and kidneys showed the highest percentage of the injected radioactivity for humans and monkeys. For humans, approximately 45% of the activity is eliminated by bladder voiding in 3.6 h, and for monkeys 60% is in the bladder content after 3 h. The critical organ is the urinary bladder wall with the highest absorbed radiation dose of 415±18 (monkeys) and 299±38 μGy/MBq (humans), in the 4.8-h bladder voiding interval model. The average value of effective dose for the adult male was estimated at 42±4.2 μSv/MBq from monkey data and 27±2 μSv/MBq from human data. CONCLUSION: Bladder, kidneys, and liver have the highest uptake of injected F-HX4 activity for both monkeys and humans. The urinary bladder wall receives the highest dose of F-HX4 and is the critical organ. Thus, patients should be encouraged to maintain adequate hydration and void frequently. The effective dose of F-HX4 is comparable with that of other F-based imaging agents.
OBJECTIVES: F-HX4 is a novel positron emission tomography (PET) tracer for imaging hypoxia. The purpose of this study was to determine the biodistribution and estimate the radiation dose of F-HX4 using whole-body PET/computed tomography (CT) scans in monkeys and humans. METHODS: Successive whole-body PET/CT scans were done after the injection of F-HX4 in four healthy humans (422±142 MBq) and in three rhesus monkeys (189±3 MBq). Biodistribution was determined from PET images and organ doses were estimated using OLINDA/EXM software. RESULTS: The bladder, liver, and kidneys showed the highest percentage of the injected radioactivity for humans and monkeys. For humans, approximately 45% of the activity is eliminated by bladder voiding in 3.6 h, and for monkeys 60% is in the bladder content after 3 h. The critical organ is the urinary bladder wall with the highest absorbed radiation dose of 415±18 (monkeys) and 299±38 μGy/MBq (humans), in the 4.8-h bladder voiding interval model. The average value of effective dose for the adult male was estimated at 42±4.2 μSv/MBq from monkey data and 27±2 μSv/MBq from human data. CONCLUSION: Bladder, kidneys, and liver have the highest uptake of injected F-HX4 activity for both monkeys and humans. The urinary bladder wall receives the highest dose of F-HX4 and is the critical organ. Thus, patients should be encouraged to maintain adequate hydration and void frequently. The effective dose of F-HX4 is comparable with that of other F-based imaging agents.
Authors: James L Tatum; Gary J Kelloff; Robert J Gillies; Jeffrey M Arbeit; J Martin Brown; K S Clifford Chao; J Donald Chapman; William C Eckelman; Anthony W Fyles; Amato J Giaccia; Richard P Hill; Cameron J Koch; Murali Cherukuri Krishna; Kenneth A Krohn; Jason S Lewis; Ralph P Mason; Giovanni Melillo; Anwar R Padhani; Garth Powis; Joseph G Rajendran; Richard Reba; Simon P Robinson; Gregg L Semenza; Harold M Swartz; Peter Vaupel; David Yang; Barbara Croft; John Hoffman; Guoying Liu; Helen Stone; Daniel Sullivan Journal: Int J Radiat Biol Date: 2006-10 Impact factor: 2.694
Authors: Judith van Loon; Marco H M Janssen; Michel Ollers; Hugo J W L Aerts; Ludwig Dubois; Monique Hochstenbag; Anne-Marie C Dingemans; Roy Lalisang; Boudewijn Brans; Bert Windhorst; Guus A van Dongen; Hartmuth Kolb; James Zhang; Dirk De Ruysscher; Philippe Lambin Journal: Eur J Nucl Med Mol Imaging Date: 2010-04-06 Impact factor: 9.236
Authors: M M Graham; L M Peterson; J M Link; M L Evans; J S Rasey; W J Koh; J H Caldwell; K A Krohn Journal: J Nucl Med Date: 1997-10 Impact factor: 10.057
Authors: J G Rajendran; K R G Hendrickson; A M Spence; M Muzi; K A Krohn; D A Mankoff Journal: Eur J Nucl Med Mol Imaging Date: 2006-07 Impact factor: 9.236
Authors: Catharina M L Zegers; Wouter van Elmpt; Bart Reymen; Aniek J G Even; Esther G C Troost; Michel C Ollers; Frank J P Hoebers; Ruud M A Houben; Jonas Eriksson; Albert D Windhorst; Felix M Mottaghy; Dirk De Ruysscher; Philippe Lambin Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Ludwig J Dubois; Natasja G Lieuwes; Marco H M Janssen; Wenny J M Peeters; Albert D Windhorst; Joseph C Walsh; Hartmuth C Kolb; Michel C Ollers; Johan Bussink; Guus A M S van Dongen; Albert van der Kogel; Philippe Lambin Journal: Proc Natl Acad Sci U S A Date: 2011-08-23 Impact factor: 11.205
Authors: Connie Yip; Philip J Blower; Vicky Goh; David B Landau; Gary J R Cook Journal: Eur J Nucl Med Mol Imaging Date: 2015-02-21 Impact factor: 9.236
Authors: Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb Journal: Antioxid Redox Signal Date: 2014-05-09 Impact factor: 8.401
Authors: Mohan Doss; Hartmuth C Kolb; Joseph C Walsh; Vani P Mocharla; Zhihong Zhu; Michael Haka; R Katherine Alpaugh; David Y T Chen; Jian Q Yu Journal: Mol Imaging Biol Date: 2014-10 Impact factor: 3.488
Authors: Catharina M L Zegers; Wouter van Elmpt; Katrin Szardenings; Hartmuth Kolb; Alan Waxman; Rathan M Subramaniam; Dae Hyuk Moon; Jacqueline C Brunetti; Shyam M Srinivas; Philippe Lambin; David Chien Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-02 Impact factor: 9.236
Authors: Hadis Honarvar; Javad Garousi; Elin Gunneriusson; Ingmarie Höidén-Guthenberg; Mohamed Altai; Charles Widström; Vladimir Tolmachev; Fredrik Y Frejd Journal: Int J Oncol Date: 2014-11-27 Impact factor: 5.650